(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...
AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...
Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback